Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7765035 | 1.00 | MMP12 (0.34) | MMP12MMP2MMP9MMP13MMP14 | |
| SCHEMBL7765130 | 0.78 | MME (0.37) | MMP2MME | |
| SCHEMBL7765135 | 0.78 | MME (0.37) | MMP2MME | |
| SCHEMBL7765144 | 0.78 | MME (0.37) | MMP2MME | |
| SCHEMBL7971454 | 0.68 | TRPA1 (0.40) | — | |
| SCHEMBL7762255 | 0.67 | MMP2 (0.49) | MMP12MMP2MMP9MMP13MMP14 | |
| SCHEMBL7762305 | 0.66 | MMP2 (0.45) | MMP12MMP2 | |
| SCHEMBL7762293 | 0.66 | MMP2 (0.45) | MMP12MMP2 | |
| SCHEMBL7762298 | 0.66 | MMP2 (0.45) | MMP12MMP2 | |
| SCHEMBL7988529 | 0.65 | ROCK1 (0.39) | FNTAPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |